Document:

EX-10.4

 Exhibit 10.4 

INTERCOMPANY LOAN AGREEMENT 

INTERCOMPANY LOAN AGREEMENT (this “Agreement”), dated as of November 18, 2013, by and between Ampio Pharmaceuticals, Inc., a
Delaware corporation (“Lender”), and Vyrix Pharmaceuticals, Inc., a Delaware corporation (“Borrower”), a wholly-owned subsidiary of Lender. 

WHEREAS, Lender and Borrower desire to establish an intercompany loan arrangement, as described below, to provide for working capital and for
any other purpose deemed necessary by Lender and Borrower. 
 NOW, THEREFORE, in consideration of the mutual promises, covenants and
conditions set forth herein, the parties hereto agree as follows: 
  

	 	1.	Loan and Repayment. 

 (a) Subject to the terms and conditions hereof, Lender agrees to
lend up to an aggregate amount of Three Million Dollars ($3,000,000) (the “Maximum Principal Amount”). 
 (b) Unless
otherwise agreed to in writing by the parties, the Maximum Principal Amount and any Cash Advances (as defined below) shall be loaned on an unsecured basis. 

(c) At any time and from time to time while this Agreement is in effect, Borrower may request to borrow from Lender an amount up to $500,000.
Each amount actually advanced to Borrower under this Agreement is herein called a “Cash Advance” and shall be listed on Exhibit A hereto. 

(d) Each request made by Borrower for a Cash Advance (a “Cash Advance Request”) shall be substantially in the form of
Exhibit B attached hereto and delivered to Lender at Lender’s address indicated in Section 6 below, or at such other address as Lender shall have designated by written notice to Borrower. Subject to the terms and conditions
contained herein, Lender shall, within 5 business days after receipt of a Cash Advance Request, deliver to Borrower the amount of the requested Cash Advance by check or wire transfer, in accordance with Borrower’s instructions. 

(e) Borrower shall repay the Cash Advances on the terms set forth herein and such other terms as the parties shall agree upon. Unless otherwise
agreed to in writing by the parties, the Cash Advances shall mature and become payable on the Termination Date (as defined in Section 2 below). 

(f) The unpaid principal amount advanced hereunder shall accrue simple interest from the date of each Cash Advance until payment or conversion
in full at a rate equal to 100% of the “Applicable Federal Rate” for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability), as
in effect from time to time. 

 (g) If all of the obligations outstanding under this Agreement have not been previously converted
(as provided in Section 3 hereof), then the outstanding principal amount advanced hereunder plus all accrued and unpaid interest thereon and all other amounts accrued under this Agreement (collectively, the “Balance”) shall be
due and payable on the Termination Date (as defined below). 
 (h) Borrower may discharge the obligations it has undertaken hereby, at any
time, by repaying the Balance, without penalty. Borrower may, without penalty, make a partial prepayment of principal plus interest in any amount at any time and may thereby reduce any required future payments hereunder. 

(i) Any payments to Lender in satisfaction of Borrower’s obligations hereunder shall be applied first to the amount of accrued interest
hereunder until such accrued interest has been paid in full, and then to any outstanding principal balance. 
 2. Term of Agreement.
The initial term for which this Agreement shall be in effect shall expire on the first anniversary of the date hereof; provided, however, that this Agreement shall automatically be renewed for successive one year terms thereafter unless either party
shall give written notice to the other party not less than 30 days prior to the expiration of any term notifying the other party that such party is terminating this Agreement upon the date on which the current term expires (the “Termination
Date”). 
 3. Conversion. 

(a) At the election of Lender, the entire Balance then outstanding under this Agreement shall be convertible into that number of shares of
common stock of Borrower as is equal to the Balance as of the date of conversion (the “Conversion Date”) divided by the fair market value per share of the common stock of Borrower as of the Conversion Date, with such fair market
value determined in good faith by Borrower’s board of directors. Lender shall deliver to Borrower notice of any such election as soon as practicable, but in any event no fewer than five (5) days prior to the proposed Conversion Date,
notifying Borrower of the conversion to be effected, including specifying the Balance (calculated as of the Conversion Date) and the Conversion Date. 

(b) Except for the rights to obtain certificates set forth in Section 3(c) below, all rights with respect to this Agreement shall
terminate upon the effective conversion or repayment of the entire Balance under this Agreement. 
 (c) As promptly as practicable after any
conversion of the Balance under this Agreement, Borrower at its expense will issue and deliver to Lender a certificate or certificates evidencing the number of full equity securities as are issuable to Lender in connection with a conversion under
this Section 3. No fractional shares of any of Borrower’s equity securities will be issued in connection with any conversion hereunder. In lieu of fractional shares which would otherwise be issuable, Borrower shall pay cash equal to the
product of such fraction multiplied by the fair market value per share of the common stock of Borrower as of the Conversion Date. 
 4.
Governing Law. This Agreement shall be governed by, construed and enforced in accordance with the laws of the State of Delaware. 

  
 2 

 5. Amendment. No waiver of any of the terms or conditions of this Agreement shall be
effective or binding unless such waiver is in writing and is signed by both of the parties hereto, nor shall this Agreement be changed, modified, discharged or terminated other than in accordance with its terms, in whole or in part, except by a
writing signed by both parties. 
 6. Notices. All communications and notices relating to this Agreement are to be sent: 

If to Lender: 

Ampio Pharmaceuticals, Inc. 

Attn: Mark D. McGregor 

5445 DTC Parkway, Suite 925 

Greenwood Village, CO 80111 

If to Borrower: 

Vyrix Pharmaceuticals, Inc. 

Attn: Mark D. McGregor 

5445 DTC Parkway, Suite 925 

Greenwood Village, CO 80111 
 or
to such other address as a party may designate to the other and such notices shall be deemed duly given three (3) days after mailed or upon delivery by hand or upon receipt of confirmed answer back if telephoned. 

7. Interpretation. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be in effect only to the extent of such prohibition or invalidity, without invalidating the remainder of
such provision or the remaining provisions of this Agreement. 
 8. Entire Agreement. This Agreement embodies the entire
understanding of the parties with respect to the subject matter hereof, and there are no further or other agreements or understandings. written or oral, in effect between the parties relating to the subject matter of this Agreement. 

9. No Third Party Rights. This Agreement shall be binding upon and inure solely to the benefit of each party hereto, and nothing in
this Agreement, express or implied, is intended to confer upon any other person any rights or remedies of any nature whatsoever under or by reason of this Agreement. 

10. Counterparts. This Agreement may be executed by the parties hereto in separate counterparts, each of which when so executed shall
be deemed to be an original and all of which taken together shall constitute but one and the same Agreement. 

  
 3 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
respective officers thereunto duly authorized, as of the date first written above. 
  

			
	AMPIO PHARMACEUTICALS, INC.
		
	By:	 	/s/ Michael Macaluso
	 Name: Michael Macaluso
 Title:
Chairman and CEO

	
	VYRIX PHARMACEUTICALS, INC.
		
	By:	 	/s/ Mark D. McGregor
	 Name: Mark D. McGregor
 Title:
Secretary and Treasurer

 [Signature Page to Intercompany Loan Agreement] 

 EXHIBIT A 

LIST OF CASH ADVANCES 
  

					
	 Date of Request
	  	Amount of Cash Advance	 
	 Cash Advance on 12/30/13            
	  	$	300,000.00	  
	 Cash Advance on 3/6/14
	  	$	500,000.00	  
	 TOTAL:
	  	$	800,000.00	  

 EXHIBIT B 

FORM OF CASH ADVANCE REQUEST 

                , 2013 

 

	To:	AMPIO PHARMACEUTICALS, INC. 

	    	Attn: 

 Dear Sir: 

We refer to the Intercompany Loan Agreement dated as of November __, 2013 (called the “Agreement”) between VYRIX
PHARMACEUTICALS, INC. and AMPIO PHARMACEUTICALS, INC. Terms defined in the Agreement have the same meanings in this Cash Advance Request. 

We hereby request pursuant to the Agreement and on             , 20     [date
of proposed Advance] a Cash Advance of $            , payable by [        ] your check or [        ] wire
transfer, in accordance with our instructions. 
  

			
	Very truly yours,
	
	VYRIX PHARMACEUTICALS, INC.
		
	By:	 	 
		
	Name:	 	 
	Title:EX-10.5

 Exhibit 10.5 

ASSIGNMENT AND ASSUMPTION AGREEMENT 

This ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Assignment”) is dated as of December 1, 2013, by and between Ampio
Pharmaceuticals, Inc., a Delaware corporation (“Assignor”), and Vyrix Pharmaceuticals, Inc., a Delaware corporation (“Assignee”), a wholly-owned subsidiary of Assignor. 

WHEREAS, Assignor desires to assign and transfer all of its rights and interests in and under the Contracts (as defined below) to Assignee and
Assignee desires to accept such assignment and transfer and to assume all such Contracts as of the date hereof, each in accordance with the terms and conditions of this Assignment. 

NOW, THEREFORE, in consideration of the mutual promises, covenants and conditions set forth herein, the parties hereto agree as follows: 

1. Assignment. Assignor hereby sells, assigns, transfers and conveys to Assignee, its successors and assigns, effective as of the date
hereof, all of Assignor’s rights, title and interest in and under the following contracts: 
 (a) Manufacturing and Supply Agreement by
and between Ethypharm S.A. and Assignor, dated as of September 10, 2012 (the “Ethypharm Contract”); 
 (b) License,
Development and Commercialization Agreement by and between Daewoong Pharmaceuticals Co., Ltd and Assignor, dated as of August 23, 2011 (the “Daewoong Contract”); 

(c) Distribution Agreement by and between FBM Industria Farmaceutica, Ltda. and Assignor, dated as of March 1, 2012 (the “FBM
Contract”); 
 (d) Asset Purchase Agreement by and between Valeant International (Barbados) SRL (formerly Biovail Laboratories
International SRL) and Assignor, dated as of December 2, 2011 (the “Valeant Contract”); 
 (e) Master Services
Agreement by and between Syngene International Limited and Assignor, dated as of June 30, 2012 (the “Syngene Contract”); and 

(f) Xerimis Inc. Proposal No. 2860032 by and between Xerimis Inc. and Assignor, dated as of June 5, 2013 (the “Xerimis
Contract” and, together with the Ethypharm Contract, the Daewoong Contract, the FBM Contract, the Valeant Contract and the Syngene Contract, the “Contracts”). 

2. Assumption. Assignee, for itself and its successors and assigns, hereby accepts Assignor’s assignment and assumes and agrees to
be bound by and solely perform, effective as of the date hereof, all of the obligations, liabilities and duties of Assignor under the Contract. 

 3. Governing Law. This Assignment shall be governed by, construed and enforced in
accordance with the laws of the State of Delaware. 
 4. Counterparts. This Assignment may be signed in any number of counterparts,
all of which together shall constitute one and the same instrument. Any party may execute and deliver this Assignment by an executed signature page transmitted by electronic scan (pdf) or a facsimile machine. 

5. Binding Effect. If and when this Assignment becomes effective, this Assignment shall be binding upon Assignor, its successors and
assigns, and shall inure to the benefit of Assignee, its successors and assigns. 
 [Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be executed by their
respective officers thereunto duly authorized, as of the date first written above. 
  

			
	 ASSIGNOR:
  

AMPIO PHARMACEUTICALS, INC.

		
	By:	 	/s/ Mark D. McGregor
	 Name: Mark D. McGregor
 Title:
  CFO

	
	 ASSIGNEE:
  

VYRIX PHARMACEUTICALS, INC.

		
	By:	 	/s/ Mark D. McGregor
	 Name: Mark D. McGregor
 Title:
  Secretary and Treasurer

 [Signature Page to Assignment and Assumption Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]